Apr 15, 2019

As market penetration improves, sustainable expansion will depend on the rate of use of cerebral oximetry monitoring technologies in a variety of indicated procedures. Efforts to increase levels of awareness regarding the cost and outcome benefits of employing cerebral oximetry monitoring are expected to foster improved uptake and support an optimistic forecast. Cerebral oximetry is a non-invasive technology that continuously monitors cerebral tissue oxygen saturation through optical techniques. More specifically, trans-cranial cerebral oximetry is a method to detect cerebral hypoxia and to avoid cerebral dysfunctions. Brain tissue saturation measurements are critical to monitoring the level of cerebral hypoperfusion. When coupled with pulse oximetry, cerebral oxygen saturation readings allow healthcare professionals to establish the effects of cerebral metabolism changes regionally and balance local cerebral oxygen supply. Key Topics Covered: 4.2.1.2 New HealthTrust Agreement Covers Drger's Line of Anesthesia Solutions 4.2.1.3 Drger and ICON Prepared to Support Hospitals with Ventilators During Times of Crisis 4.2.1.4 Drger First to Achieve DIACAP Certification for Patient Monitoring and Clinical IT Systems 4.2.1.5 Drger Infinity M300 Monitor Now Features FIPS Security 4.2.1.6 Drger First to Achieve DIACAP Certification for Patient Monitoring and Clinical IT Systems 4.2.1.7 Drger to Discuss Alarm Management and Strategies for Eliminating Alarm Fatigue at HIMSS16 4.2.2 Edwards Lifesciences 4.2.2.2 Edwards' Acumen Hypotension Prediction Index Launches In The U.S. 4.2.2.3 Edwards Lifesciences Reports Fourth Quarter Results 4.2.2.4 Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference 4.2.2.5 Edwards Acquires Harpoon Medical 4.2.2.6 Edwards' Advanced Hemodynamic Monitoring Platform Receives FDA Clearance 4.2.2.7 Edwards Lifesciences Reports Fourth Quarter Results 4.2.2.8 Edwards Lifesciences Completes Acquisition Of Valtech Cardio 4.2.2.9 Edwards Receives CE Mark For Hypotension Probability Indicator 4.2.2.10 Edwards Lifesciences Reports Second Quarter Results 4.2.2.11 Leslie Heisz Appointed To Edwards Lifesciences Board Of Directors 4.2.2.12 Edwards Lifesciences Reports First Quarter Results 4.2.2.13 Steven Loranger Appointed To Edwards Lifesciences Board Of Directors 4.2.2.14 Edwards Lifesciences Reports Fourth Quarter Results 4.2.3 Fukuda Denshi 4.2.3.1 Fukuda Denshi Introduces the UF-760AG Color Portable Ultrasound System in the U.S. A High Performance Color Portable Ultrasound Unit Designed for a Wide Array of Specialty Markets 4.2.3.2 Hospitals, Healthcare Providers to Save with the Fukuda Denshi USA Inc. and Amerinet Choice License and Supply Agreement 4.2.4 GE Healthcare